AbbVie today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the ...

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

Shiong’s portfolio saw a slight drop over past 12 months as the value of his stake in Culver City immunotherapy firm ...

A new study finds that EULAR/ACR criteria identify more systemic lupus erythematosus cases among patients with interstitial ...

A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...

The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer Patients with ...